Regional health inequalities of anticancer drug accessibility under the National Drug Price Negotiation in China: a decomposition analysis Authors: Bingbing Tuo, Junnan Jiang, Haokai Zhao, Yiqing Mao, Yufei Ren Published: 2026 ABSTRACT AbstractBackgroundEquitable access to anticancer drugs is a central concern in oncology care. China initiated National Drug Price Negotiation (NDPN) in 2016, which has been associated with improved accessibility and equity in anticancer drugs. This study aims to evaluate the current regional equity in the provision of negotiated anticancer drugs in China.MethodsThe study collected data on the availability of anticancer drugs negotiated by public platforms across 31 provinces. We collected province-level data on the availability of negotiated anticancer drugs in hospitals and pharmacies across 31 provinces and calculated GDP-related concentration indices (CIs). A decomposition analysis of CIs was conducted to identify determinants of inequity, and CIs were further computed within the breast cancer subgroup.ResultsThe CIs were 0.125 for hospitals and 0.139 for pharmacies, indicating pro-rich inequality in the regional provision of negotiated anticancer drugs, with higher-income eastern regions offering more hospitals and pharmacies with anticancer drugs. Medical insurance expenditures (56.209%) and inpatient costs (46.745%) exacerbated hospital supply inequality. The number of pharmacists in pharmacies (63.845%) was the primary positive contributor to pharmacy access inequality. Among breast cancer drugs, Abemaciclib and Nalatinib Maleate exhibited higher CIs of 0.244 and 0.223.ConclusionThe regional distribution of negotiated anticancer drugs reveals substantial disparities, with affluent regions more likely to access these medications through well-resourced hospitals and pharmacies. Health expenditure and financing mechanisms further amplify these inequalities. Even within similar indications, disparities persist in the availability of different drugs. Future initiatives should prioritize measures to ensure drug access in impoverished and remote areas.Keywords: Anticancer drug accessibility, National Drug Price Negotiation, Inequality, Determinants, Concentration Index Background Cancer constitutes a significant public health challenge in both developed and developing nations. According to the 2022 National Cancer Report issued by the National Cancer Center of China, the country reported 4.064 million new cancer cases, with a world-standardized incidence rate of 186.46 per 100,000 individuals [1]. However, current treatment regimens for many cancers frequently fail to contain disease progression, underscoring the paramount importance of innovative anticancer drugs [2]. The financial burden of cancer treatment appears catastrophic for Chinese patients, with approximately half resorting to borrowing or incurring debt, and 10% reporting foregoing medical care due to cost concerns [3]. Many patients cannot afford targeted anticancer therapies [4]. To improve the utilization and accessibility of innovative drugs, the Chinese government introduced the National Drug Price Negotiation (NDPN) policy in 2016 [5]. This national-level negotiation mechanism between the central government and pharmaceutical companies primarily aims to reduce the prices of innovative drugs with high clinical value [6]. Pharmaceutical companies aspire to secure entry into the National Reimbursement Drug List (NRDL) by offering substantial price reductions, which can swiftly amplify their market share in China through volume gains at the expense of margins. As of January 2023, the NRDL included 430 negotiated drugs, a large proportion of which were anticancer drugs. This policy logic is not unique to China. Drug price negotiation policies have also been adopted in other settings, including Europe and the United States [7], based on the expectation that reimbursement listing can increase sales volume and market share despite lower unit prices. Consequently, patients may gain access to reimbursed drugs, potentially improving affordability and the cost-effectiveness of treatment. To improve access to negotiated drugs, China implemented the “dual-channel” system in 2021, enabling dispensing through both designated hospitals and pharmacies [8]. Previously, most anticancer drugs followed a “hospital-first, then reimbursement” path, allowing sufficient time for market promotion, clinical experience accumulation, expert endorsement, and widespread use. However, the recent reform reversed this sequence to “reimbursement-first, then hospital,” which placed greater pressure on hospitals to achieve timely formulary entry and rapid clinical adoption. In practice, some negotiated drugs encounter difficulties in hospital entry, resulting in delayed supply. Recognizing pharmacies’ broad geographic coverage, market responsiveness, and service flexibility, policymakers positioned pharmacies as a complement to designated medical institutions. To address the “hospital-entry challenge,” pharmacies were integrated into the negotiated drug supply network alongside medical institutions, forming a dual-channel reimbursement and dispensing system that improved drug accessibility. Previous studies on NDPN have primarily concentrated on the policy’s impact on hospital procurement prices [9], volumes, and expenditures [10], with inadequate attention given to the accessibility of these negotiated drugs. Although prior studies have examined barriers and delays in access to anticancer medicines in Europe [11] and reviewed financing strategies for high-cost anticancer drugs [12], equity-focused analyses of anticancer drug accessibility remain limited. Compared with the existing literature on medication equity, this study contributes by focusing on oncology drugs under the NDPN and by assessing supply-side availability across both hospitals and pharmacies. We also evaluated interprovincial inequality in access to anticancer drugs and decomposed this inequality from the perspectives of healthcare provider resources and health expenditure/financing to identify key drivers of inequity. Methods Data sources We obtained information on hospitals and pharmacies dispensing nationally negotiated drugs from the National Healthcare Insurance Service Platform, a public service platform serving both residents and enterprises. Within the “Public Inquiry” module, a dedicated search function (“Facilities Dispensing National Negotiated Drugs”) provides the names and addresses of hospitals and pharmacies dispensing these medications. The data are derived from submissions by enterprises and undergo regular updates within the system to ensure currency. We compiled province-level counts (as of June 2024) of hospitals and pharmacies across China that dispensed anticancer drugs included in the nationally negotiated drug portfolio. Measurement Determinants Because determinants of negotiated drug accessibility may differ between hospitals and pharmacies, we grouped covariates into two domains: healthcare provider resources and health expenditure/financing (Table 1). Healthcare provider resources included the number of hospitals, beds, pharmacy (chain and retail), pharmacists (hospitals and pharmacies), and with bachelor’s degrees or above. According to the classification of hospitals by the Chinese government, the specific criteria include the number of beds, the level of medical technology and management, and the status of equipment [18]. n practice, secondary and tertiary hospitals are the primary facilities equipped to provide anticancer medications for patients with malignant tumors. Table 1The definition and unit of negotiated anticancer drug accessibility inequalities determinantsDeterminantsDefinitionUnitPannel A: Healthcare provider resourcesNumber of secondary and tertiary hospitalsaThe number of local and regional hospitals that can provided comprehensive and specialist health services [20].Number of physicians per 1,000 inhabitantsaCertificate physicians/ inhabitants*1000 [21]per 1 000 inhabitantsNumber of hospital beds per 1000 inhabitantsaHospital beds/ inhabitants*1000 [22]per 1 000 inhabitantsNumber of chain pharmaciesbNumber of chain pharmacies licensed as drug distributors in each province [23]Number of retail pharmaciesbNumber of retail pharmacies licensed as drug distributors in each province [24]Number of pharmacists in hospitalbNumber of pharmacists who work in hospital [25]Number of pharmacists in pharmaciesbNumber of pharmacists who work in pharmacies [26]Number of pharmacists holding a bachelor’s degree or abovebNumber of pharmacists who had a bachelor’s degree, master degree or doctor degree [27].Pannel B: Health expenditure and financingTotal health expenditure (THE) per capitaaThe total cost raised for carrying out health service activities in a region in a year/ inhabitants [28].per capita, $The average outpatient cost per visitcThe outpatient cost/outpatient visit [29]per visit, $The average inpatient cost per staycThe inpatient cost/inpatient stay [30]per stay, $Basic Medical Insurance coverage populationcURRBMI coverage population+ UEBMI coverage population [31]BillionMedical Insurance expenditures per capitacMedical Insurance expenditures/ insured reimbursement population [32]per capita, $Number of cities involved with DRGs/DIPdCities participating in the national DRGs/DIP reform pilot [33]data sources a: China Health Statistical Yearbook 2022b: Drug administration statistical annual data 2023c: Statistical Bulletin on the Development of National Medical Security Undertakings in 2023d: National Healthcare Insurance Service Platform The definition and unit of negotiated anticancer drug accessibility inequalities determinants data sources a: China Health Statistical Yearbook 2022 b: Drug administration statistical annual data 2023 c: Statistical Bulletin on the Development of National Medical Security Undertakings in 2023 d: National Healthcare Insurance Service Platform Health expenditure and financing included the total health expenditure (THE), average outpatient/inpatient cost per stay, basic medical insurance coverage population, medical insurance expenditures per capita and number of cities involved with Diagnosis Related Groups (DRGs) or Data-driven Insurance Payment (DIP). China’s current basic medical insurance system comprises two primary categories: the Urban and Rural Residents Basic Medical Insurance (URRBMI), which encompasses both rural and urban populations, and the Urban Employee Basic Medical Insurance (UEBMI), targeting the formally employed. From a universal health coverage perspective, we collected data on the populations covered by these two insurance schemes in each province. Payment mechanisms are recognized as pivotal factors influencing the utilization of high-cost innovative drugs [19]. China has progressively piloted case-based payment systems in numerous cities, and we recorded the number of cities in each province that had joined national DRGs/DIP pilot programs. Data on determinants were extracted from the China Statistical Yearbook, the China Health Statistical Yearbook (2022 edition), Drug Administration Statistical Annual Data 2023, and the National Healthcare Insurance Service Platform. The analysis covered 31 provinces, autonomous regions, and municipalities directly under the central government; Macau, Hong Kong, and Taiwan were excluded because of inconsistencies in data standards. Outcome Penchansky and Thomas conceptualized access as comprising five dimensions: availability, accessibility, accommodation, affordability, and acceptability [13]. Measuring access has often been limited to two of these five dimensions, namely availability and affordability [14]. In the WHO project, availability is defined as the number or proportion of institutions equipped with or storing drugs [15]. In China, the “dual-channel” system ensures that patients can obtain negotiated drugs from hospitals or pharmacies. Therefore, a larger number of hospitals or pharmacies stocking a given negotiated drug indicates greater patient access to that drug. Accordingly, the number of hospitals or pharmacies that can dispense negotiated drugs was used as a measure of drug availability [16]. In this study, the primary outcome was the number of hospitals and pharmacies in each province that could dispense the same negotiated anticancer drug, as an indicator of availability. Affordability is typically measured using patient drug expenditure [17]. However, this study focused on provider-side data, and patient-level economic burden data were not available. Moreover, given the uniform pricing strategy adopted for negotiated drugs across provinces in China, significant variation in affordability is not observed. Subgroup To assess heterogeneity in accessibility across anticancer drugs, we conducted a breast cancer subgroup analysis using drug names listed in the NRDL (2023 edition). These drugs were explicitly indicated for breast cancer treatment within their approved indications. We searched manufacturer information and classified drugs as domestic or imported. Statistical analysis Concentration curves GDP-related inequality was assessed using the concentration index (CI). CI is widely used to measure equity in health services, including drug accessibility [34]. The CI is rigorously defined based on the Concentration Curve (CC) [35]. The CC is a graphical representation that plots the cumulative distribution of a health-related variable against the cumulative distribution of the population, stratified according to an economic index ranging from the poorest to the richest segments. Under perfect equity, when the outcome is independent of economic status, the CC coincides with the 45-degree line (the “line of equality”), and the CI equals zero [36]. Deviations from this line indicate inequality. A CC above (below) the line of equality suggests a concentration of the outcome among poorer (richer) populations, and the CI is bounded between − 1 and + 1. The GDP-related concentration curve for negotiated drug provision plots shows the cumulative proportion of hospitals or pharmacies capable of providing negotiated drugs versus the cumulative proportion of provinces ranked by GDP. This curve enables assessment of how negotiated drug provision is distributed across provinces with different GDP levels. It therefore provides a visual representation of relative equity in provision. Similar approaches have been used in prior studies [37]. Majid Davari et al. developed relevant models to measure equity in access to pharmaceutical services using CI [38]. A latest analysis of drug consumption and expenditure on essential cancer drugs in 40 countries and regions from 2012 to 2022 by the WHO also used CI to measure the equity of essential cancer drugs in different income countries [39]. Decomposition of concentration index Wagstaff (2003) demonstrated that the concentration index can be decomposed into the contributions of individual factors to income-related inequality in health outcomes. Each of these contributions is quantitatively represented by the product of two components: firstly, the sensitivity of health outcomes (y) to variations in the specific factor; and secondly, the extent of income-related inequality inherent within that factor. This approach applies to linear additive regression models of health outcomes and can be expressed as follows: the concentration index for can be written as follows: Where is the mean of y, is the mean of , is the CI for , and is the generalized CI for the error term (). Equation (b) shows that C is equal to a weighted sum of the concentration indices of the k regressors, where the weight for is the elasticity of y with respect to . The residual component captured by the last term reflects the income-related inequality in health that is not explained by the systematic variation in the regressors by income, which should approach zero for a well-specified model. Results Descriptive statistics Table 2 represents the descriptive statistics. the mean number of hospitals per province dispensing negotiated anticancer drugs was 26.142 (SD 18.055), compared with 17.911 (SD 15.283) pharmacies. In terms of Healthcare Provider Resources, each province boasted an average of 274.419 secondary and tertiary hospitals, with 3.110 physicians and 6.706 hospital beds per 1,000 population. The mean numbers of chain and retail pharmacies were 12,438.520 and 9,076.323, respectively. Regarding Healthcare Expenditure and Financing, the average per capita health expenditure per province was USD 783.476, with an average outpatient visit cost of USD 49 and an average inpatient admission cost of USD 1,862.464. The average basic medical insurance coverage per province encompassed 439.133 million individuals, with an annual expenditure from medical insurance funds amounting to USD 6.510. Table 2Characteristics of variables in 31 provincesVariablesMeanStandardHospitals can offer negotiated drugs26.14218.055Pharmacies offer negotiated drugs17.91115.283GDP ($)11362.1304983.863Panel A: Healthcare provider resourcesNumber of Secondary and tertiary Hospitals274.419135.178Number of physicians per 1,000 inhabitants3.1100.503Number of hospital beds per 1,000 inhabitants6.7060.927Number of chain pharmacies12438.52010370.680Number of retail pharmacies9076.3236688.397Number of pharmacists in hospital760.839796.021Number of pharmacists in pharmacies23034.42016962.010Number of pharmacists holding a bachelor’s degree or above2784.3551902.299Panel B: Health expenditure and financingTHE($)783.476294.189The average outpatient cost per visit ($)49.08312.899The average inpatient cost per stay ($)1862.464641.471Basic Medical Insurance coverage population (million)439.133293.855Medical Insurance expenditures per capita ($)6.5105.601Number of cities involved with DRGs/DIP2.6452.260 Characteristics of variables in 31 provinces Figure 1 illustrates the distribution of hospitals and pharmacies equipped with negotiated anticancer drugs. Both hospitals and pharmacies in eastern regions showed higher availability of negotiated drugs, with the disparity appearing more pronounced for hospitals. Furthermore, coastal areas tend to possess a greater number of equipped hospitals and pharmacies compared to their central counterparts. Conversely, remote and economically underdeveloped provinces in western regions often confront limited availability of these medications. Figure 2 presents the concentration curves for hospitals and pharmacies. The concentration indices were 0.125 for hospitals and 0.139 for pharmacies, further indicating pro-rich inequality in negotiated drug provision. Distribution of hospitals and pharmacies equipped with negotiated anticancer drugs with provinces in China Concentration curves for hospital and pharmacy equipped with negotiated anticancer drugs with provinces in China Decomposition of concentration index Table 3 illustrates the CI, elasticity, absolute contribution, and percentage contribution of each variable to inequality in hospital-based access to negotiated anticancer drugs. Medical insurance expenditures, inpatient cost, and medical insurance coverage emerged as the top contributors, accounting for 56.209%, 46.745%, and 36.370% of the inequality, respectively. These variables made positive contributions to inequality, indicating a pro-rich distribution. By contrast, outpatient cost and THE made the largest negative contributions, indicating a relative pro-poor effect. Variables with very small percentage contributions were retained in Table 3 for completeness but were not emphasized in the interpretation. Table 3Determinants of negotiated anticancer drugs access inequalities in hospitalsVariableselasticityCIcontributionpercentage contributionNumber of Secondary and tertiary Hospitals*-14.167-0.0070.0930.740Number of physicians per 1,000 inhabitants21.6840.0320.6985.583Number of hospital beds per 1,000 inhabitants-37.498-0.0321.1999.58Number of pharmacists in hospital*7.465-0.006-0.048-0.383THE-22.9880.110-2.528-20.210The average outpatient cost per visit-44.4160.091-4.062-32.472The average inpatient cost per stay48.9980.1195.84746.745Basic Medical Insurance coverage population79.9510.0574.54936.370Medical Insurance expenditures per capita22.4880.3137.03156.209Number of cities involved with DRGs/DIP*3.1550.0860.2712.163This table retains all independent variables included in the decomposition model to preserve the mathematical integrity of the decomposition. Variables marked with an asterisk * exhibit relatively low absolute values of contribution rates (e.g., the number of secondary/tertiary hospitals and the number of pharmacists), indicating that their explanatory power for current regional inequalities is limited; therefore, they are not discussed in detail as core determinants in the qualitative discussion Determinants of negotiated anticancer drugs access inequalities in hospitals This table retains all independent variables included in the decomposition model to preserve the mathematical integrity of the decomposition. Variables marked with an asterisk * exhibit relatively low absolute values of contribution rates (e.g., the number of secondary/tertiary hospitals and the number of pharmacists), indicating that their explanatory power for current regional inequalities is limited; therefore, they are not discussed in detail as core determinants in the qualitative discussion Table 4 shows that the disproportionate contributions to the unequal accessibility of negotiated anticancer drugs are primarily attributed to pharmacists in pharmacies and medical insurance expenditures, accounting for 63.854% and 32.341%, respectively. These factors act as positive contributors to inequality, signifying their benefit to the affluent population at the expense of the less well-off. Conversely, retail pharmacies and THE emerge as the primary negative factors, which favor the poor while potentially disadvantaging the wealthy. Similarly, Table 4 reports all variables from the prespecified decomposition model, while the discussion focuses on contributors with larger absolute percentage contributions. Table 4Determinants of negotiated anticancer drugs access inequalities in pharmacyVariableselasticityCIcontributionpercentage contributionNumber of chain pharmacies-42.6040.022-0.916-6.607Number of retail pharmacies-51.1460.057-2.895-20.875Number of pharmacists in pharmacies110.4230.0808.85563.854Number of pharmacists holding a bachelor’s degree or above*-1.0670.092-0.098-0.709THE-31.4760.110-3.461-24.960Basic Medical Insurance coverage population33.3010.0571.89513.664Medical Insurance expenditures per capita14.3450.3134.48532.341Number of cities involved with DRGs/DIP14.0250.0861.2038.673Although the contribution rates of variables such as the number of highly educated pharmacists are minimal, they are retained in the table to present a comprehensive picture of the factors influencing inequality. Variables with contribution rates below 1% are generally considered minor factors in policy interpretation Determinants of negotiated anticancer drugs access inequalities in pharmacy Although the contribution rates of variables such as the number of highly educated pharmacists are minimal, they are retained in the table to present a comprehensive picture of the factors influencing inequality. Variables with contribution rates below 1% are generally considered minor factors in policy interpretation The CI of breast cancer We compiled a breast cancer drug subgroup from the negotiated drug list and calculated the CI for each drug. Table 5 highlights substantial variations in equity of access across different drugs, and all CIs are positive, indicating better accessibility to breast cancer medications in high-income regions. Among hospital-dispensed drugs, Abemaciclib and Nalatinib Maleate exhibit notably higher CIs of 0.244 and 0.223, respectively, suggesting more abundant availability in provinces with higher GDPs and potential challenges in accessing them in less developed areas. In contrast, within pharmacy-available medications, Mitoxantrone Hydrochloride registers a CI of 0.292, favoring wealthier regions. Intriguingly, its CI for hospital accessibility stands at a mere 0.073, closely approaching the line of absolute equity, suggesting a degree of complementarity between settings. Table 5Concentration index of breast cancer negotiated drug for hospital and pharmacyDrugsSourcesHospitalsPharmacyMitoxantrone HydrochlorideDomestic0.0730.292InetetamabDomestic0.1400.127Trastuzumab EmtansineImported0.1910.099TrastuzumabImported0.1320.159Pyrrolitinib MaleateDomestic0.0990.089AbemaciclibImported0.2440.145Nalatinib MaleateDomestic0.2230.147Dalpiciclib IsethionateDomestic0.1050.095 Concentration index of breast cancer negotiated drug for hospital and pharmacy Discussion Our study identified a positive GDP-related CI for access to negotiated anticancer drugs, indicating that hospitals and pharmacies in economically developed eastern regions were more likely to provide these medications. Decomposition of the CI further showed that medical insurance expenditures, inpatient costs, and insurance coverage contributed to inequality in hospital-based access, whereas the number of pharmacists was the main contributor to inequality in pharmacy-based access. In the breast cancer subgroup, we also observed heterogeneity in inequality patterns across drugs and dispensing settings. The findings indicated a pro-rich pattern in access to negotiated anticancer drugs. Patients in eastern coastal regions often have stronger purchasing power, and even after national price negotiation, some anticancer drugs may remain financially burdensome for lower-income patients. Consequently, the higher-income populations in these regions may generate greater demand for negotiated anticancer drugs [40]. Additionally, these economically developed areas tend to harbor hospitals with superior medical services [41], and many top-tier hospitals in China are concentrated in the east. This concentration may further widen access disparities by attracting large numbers of patients with malignant tumors who seek high-quality care. High-GDP regions also tend to support more pharmacy chains, which may further reinforce economically driven disparities in access to negotiated anticancer drugs. Such disparities have also been noted in other studies [11] [42]; for instance, countries in the eastern and southeastern regions of the European Union often have reduced access to novel anticancer drugs, potentially due to lower healthcare system capacity and specialization, as well as limited public awareness, societal dialogue, and political will [43]. However, a French study, after controlling for case mix, found no disparities among hospitals and regions in the utilization of costly anticancer drugs [44]. These differences across studies may stem from variations in access policies both within and between countries. Compared with health service resources, medical expenditure and financing variables exerted a stronger influence on GDP-related inequality in access to negotiated anticancer drugs. Both basic medical insurance expenditures and hospitalization costs contribute significantly to augmenting this inequality. China’s basic medical insurance system is partly characterized by a revenue-driven expenditure structure, meaning that higher insurance expenditures often reflect stronger local financing capacity and, in turn, greater capacity to support anticancer drug use. Provinces with higher GDP also have greater fiscal capacity to subsidize medical insurance, which may further amplify regional disparities. Rossana Ruiz et al. observed the average expenditure per newly diagnosed cancer patient in Latin America is a mere 7.92$, compared with 183$, 244$, and 460$ in the United Kingdom, Japan, and the United States, respectively. These disparities underscore the profound inequity and inadequate resource allocation for cancer care and control within Latin America [45]. Another study observed that hospital-based DRGs curtailed access to oral anticancer medications [46]; In contrast, our results suggest that the number of cities participating in DRGs/DIP was not a major contributor in this analysis. This may be attributed to China’s current approach of employing separate, exceptional reimbursement policies under medical insurance to facilitate the utilization of negotiated anticancer drugs. High-cost anticancer drugs negotiated under such schemes are excluded from the payment amounts allocated for DRGs. Our study also shows that the quantity of registered pharmacists in pharmacies contributes to widening disparities in access to negotiated anticancer drugs. This phenomenon may stem from the higher concentration of pharmacists in pharmacies located in developed eastern provinces, which facilitates the provision of negotiated anticancer drugs. Pharmacies with more pharmacists may also be more likely to obtain local authorization to dispense anticancer medications. Pharmacists, especially oncology pharmacists, play a critical role in optimizing anticancer drug use through medication storage, dispensing, prescription review, monitoring, and patient education [47]. At present, most chemotherapy prescriptions in China are still issued by hospitals, and community or retail pharmacies mainly provide dispensing and medication counseling. Evidence comparing internal health-system specialty pharmacies with external specialty pharmacies has also suggested higher patient trust in hospital-based pharmacy services [48]. Nevertheless, amidst the expanding use of oral anticancer medications [49], pharmacies are poised to assume an increasingly significant role in the future. As highlighted by Penchansky and Thomas, a higher density of pharmacies is observed in urban areas, with increased pharmacy density correlating with enhanced access to medications [50]. While access to pharmacies has improved in high-income regions, two studies have noted exceptions to this trend [51] [52]. Significant disparities exist in the availability of pharmacies in impoverished communities compared to wealthier ones, where pharmacies often exhibit limited stock and operating hours. Within the breast cancer subgroup, the observed inter-drug variation in CIs should be interpreted cautiously, because these agents differ in molecular subtype, treatment line, administration route, and monitoring and diagnostic requirements. For instance, Abemaciclib is primarily used for HR-positive/HER2-negative disease [53], whereas Trastuzumab Emtansine is used for HER2-positive disease [54]. Accordingly, the heterogeneity is more likely to reflect a combination of clinical adoption patterns and supply-side and institutional factors after NRDL listing, such as differences in hospital formulary uptake, procurement incentives, dual-channel implementation, and reimbursement restrictions, rather than efficacy evidence alone or drug origin [55]. As an innovative reform, the NDPN has effectively improved accessibility and affordability of anticancer medications for residents. The largest single payer of China’s medical insurance has taken advantage of its huge market to make the NRDL negotiations more attractive to pharmaceutical companies, promoting their participation and price reduction. In addition, unified national pricing and strong policy implementation may help reduce regional differences in negotiated drug expenditures. But it still entails potential unintended ramifications. Studies have pointed out that when a large number of innovative drugs fail to secure inclusion in the NRDL, patient access may be hindered, either due to delayed market launch or unfavorable pricing concessions imposed on pharmaceutical manufacturers [56] [57]. Such a dilemma has led many pharmaceutical firms to perceive the policy as undermining their profit margins, in turn prompting some to withdraw from the negotiation process, delay their product rollouts in the Chinese market, or even exit the domestic market entirely ultimately curbing patients’ access to essential medications. Moreover, the bleak revenue prospects may dampen pharmaceutical firms’ enthusiasm for investing in research and development (R&D), which could ultimately jeopardize long-term pharmaceutical innovation [58]. To further facilitate access to innovative anticancer drugs, the Chinese government could subsequently expedite payments for negotiated anticancer drugs and incorporate their utilization into the performance evaluation of public medical institutions. A sound monitoring system should be integrated into the medical insurance system to track negotiated drug use and assess local implementation performance [39]. Concurrently, addressing the inequities in negotiated anticancer drugs access among residents in remote, particularly rural, areas necessitate strategies such as expanding service capacity in hospitals or pharmacies. China could also explore the co-payment of innovative drug subsidies for underserved regions and ensure the strong implementation of separate payment policies for negotiated drugs [57]. This study has several limitations. Firstly, due to the unavailability of certain drugs in hospitals or pharmacies within specific cities, our equity assessment was conducted solely at the provincial level rather than the city level. This approach may mask substantial within-province variation in medical resources and service demand. In particular, chain pharmacies are often concentrated in provincial capitals, whereas retail pharmacies may play a larger role in remote rural areas. Such pharmacy-level heterogeneity may also shape the policy effects of the NDPN and may therefore limit the comprehensiveness of our findings. Secondly, we did not examine disparities in negotiated anticancer drug provision between public and private hospitals. Although this issue has been explored in prior studies, most cancer care in China is still delivered through public hospitals, and future research should investigate this dimension further. Thirdly, due to the lack of morbidity and mortality data for various tumor types across the sampled provinces, we were unable to incorporate incidence or mortality rates for standardization and calibration in the concentration index calculation and decomposition process. Conclusion This study reveals a pronounced pro-rich bias in the provision of negotiated anticancer drugs across regions under the NDPN policy. Provinces with higher GDPs boast a greater number of hospitals and pharmacies authorized to dispense such medications. Variables such as the THE, the average inpatient cost per stay, and the number of pharmacists in pharmacies contribute to this inequality. Consequently, supplementary policies are warranted by the government to facilitate timely access to negotiated anticancer drugs for cancer patients residing in remote and impoverished areas, thereby enhancing health equity. Acknowledgements The present study was funded and supported by the Zhongnan University of Economics and Law. Abbreviations Concentration Curve Concentration Indices Data-driven Insurance Payment Diagnosis Related Groups Gross Domestic Product National Drug Price Negotiation National Reimbursement Drug List total health expenditure Urban and Rural Residents Basic Medical Insurance Urban Employee Basic Medical Insurance Author contributions HZ, JJ and MY were responsible for data cleaning and data analysis. Pro Tuo contributed in revising the initial draft and writing the final manuscript. Prof Ren had full access to all of the data in the study and was responsible for research design, data collection and full-text language editing. Funding This study was funded by The National Natural Science Foundation of China (No.72404284), the Natural Science Foundation of Hubei Province (2024AFB422) and the Fundamental Research Funds for the Central Universities, Zhongnan University of Economics and Law, “Study on the coordination and integration mechanism of global budget on the integration of medical care and prevention of county medical alliance from the perspective of holistic governance” (2722024BQ054). Data availability The datasets analysed during the current study are available in the *National Healthcare Insurance Service Platform* , https://fuwu.nhsa.gov.cn. Declarations Ethics approval and consent to participate All data was collected from public platform or yearbook, and no personal information is involved. Therefore, this paper did not require a separate ethics approval. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets analysed during the current study are available in the *National Healthcare Insurance Service Platform* , https://fuwu.nhsa.gov.cn.